Ordinary and Extraordinary General Meeting of April 12, 2023
Montrouge, France, March 24, 2023
Ordinary and Extraordinary General Meeting of April 12, 2023
Procedures for Obtaining Information and Preparatory Documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France.
The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches parisiennes dated March 24, 2023.
The information and preparatory documents for this General Meeting are made available to the Company's shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the Commercial Code are available on the Company's website (www.dbv-technologies.com).
Any shareholder wishing to receive these documents by post or electronically may make a request until midnight, Paris time, on April 7, 2023 (i.e., the fifth day before the General Meeting) by contacting the Company at investors@dbv-technologies.com. For bearer shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an intermediary, in accordance with Article L. 211-3 of the Monetary and Financial Code.
Webcast of the Annual General Meeting
On April 12, 2023, starting at 10:00 a.m. CET (4:00 a.m. ET), the General Meeting will be webcast live on the Company's website www.dbv-technologies.com.
Shareholders will also be able to access a replay of the General Meeting on the Company's website for two years after this Meeting.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for peanut-allergic children and the potential benefits of EPIT™. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission (“SEC”), and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Transfer of Harvia's own shares as rewards under the incentive program30.5.2023 19:35:00 CEST | Press release
Harvia Plc, Stock Exchange Release, May 30, 2023 at 8:35 p.m. EEST The Board of Directors of Harvia Plc has on 3 May 2023 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2020–2022 of the company’s share-based incentive program launched in 2020. In the share issue, 9,109 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the program-specific terms and conditions. After the transfer of shares under the incentive program and the shares transferred at the same time as part of the board remuneration, the company holds a total of 9,637 own shares. The decision on the transfer of shares is based on the authorization granted to the Board of Directors by the Annual General Meeting on 20 April 2023. No new shares shall be issued in conn
Transfer of Harvia’s own shares as part of remuneration of the Board30.5.2023 19:30:00 CEST | Press release
Harvia Plc, Stock Exchange Release, 30 May 2023 at 8:30 p.m. EEST Based on the decision of the General Meeting held 20 April 2023, Harvia Oyj has on 30 May 2023 transferred a total of 2,328 own shares possessed by the company to members of the Board of Directors of Harvia Oyj as part of the Board’s remuneration. After the transfer of shares as part of the board remuneration and the shares transferred at the same time under the incentive program, the company holds a total of 9,637 own shares. Based on the decision of the General Meeting of Harvia Oyj, the monthly remuneration of the Board members will be paid in company shares and in cash in such a way that approximately 40 per cent of the total monthly remuneration will be paid in company shares purchased at a price determined in public trading on Nasdaq Helsinki Ltd and approximately 60 per cent will be paid in cash. The company will pay any costs and transfer tax related to the purchase of company shares. In case the remuneration can
Vesting af warranter samt ledende medarbejderes transaktioner30.5.2023 19:18:09 CEST | pressemeddelelse
Selskabet har dags dato modtaget meddelelse om at Direktion og bestyrelse ønsker at exercise ialt 5.983.524 stk. warranter fra tildelingsåret maj 2020 (Selskabsmeddelelse 20/2020). Warrantprogrammet blev tildelt direktion og bestyrelse i maj 2020, og indehaverne af warranterne udnytter nu deres respektive programmer, og herefter udestår ingen aktieoptioner fra tildelingsåret maj 2020. Udnyttelseskursen er ved tildelingen i maj 2020 fastsat til DKK 1,53 pr. aktie af nominelt DKK 0,5, jf. selskabsmeddelelse 20/2020. Selskabet har som led i udnyttelsen af aktieoptionerne afhændet 5.983.524 stk. egne aktier til et samlet beløb på DKK 9.154.791,72, og således foretages der ingen kapitalforhøjelse i forbindelse med udnyttelsen af aktieoptionerne. Selskabets egen aktiebeholdning er efter frasalget reduceret til i alt 0 aktier. I forbindelse med gennemførelsen af ovenstående transaktioner har selskabet modtaget vedhæftede indberetninger fra direktionen og bestyrelsens respektive transaktioner.
EMGS: Notice of Annual General Meeting30.5.2023 18:30:00 CEST | Press release
Notice is hereby given of the annual general meeting of Electromagnetic Geoservices ASA ("EMGS" or the "Company"). The annual general meeting will be held at the Company's offices in Karenslyst Allé 4, 4(th) floor, 0278 Oslo, Norway on 21 June 2023 at 12:00 local time. The calling notice is attached to this stock exchange notification, and will, together with all appendixes and the Company's annual report for 2022 be published on the Company's webpage www.emgs.com. Contact Anders Eimstad, Chief Financial Officer, +47 948 25 836 About EMGS EMGS, the marine EM market leader, uses its proprietary electromagnetic (EM) technology to support oil and gas companies in their search for offshore hydrocarbons. EMGS supports each stage in the workflow, from survey design and data acquisition to processing and interpretation. The Company's services enable the integration of EM data with seismic and other geophysical and geological information to give explorationists a clearer and more complete unde
Monument Heads Toward Commercial Production at Selinsing Gold Mine30.5.2023 18:21:56 CEST | Press release
VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) ("Monument" or the "Company") is pleased to update the progress at the Selinsing Sulphide Project. The ramp-up of the flotation plant has made great headway, with the mill feed rate of 113 dry tonnes per hour achieved, being 95% of the design capacity of 119 dry tonnes per hour. The plant construction and mine development consumed a total of $18 million, in line with the budget. President and CEO Cathy Zhai commented, “We are very pleased with the flotation plant ramp-up progress as we head towards full commercial production. We have commenced sulphide production in January 2023 and continue testing and adjusting to improve plant performance through the action plan. Despite several incidental plant shutdowns during March to May, the plant is expected to reach its near or full production level by June 2023, within the planned ramp up period of three to six months. To date, th